Cargando…

Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?

The appearance of vitiligo and spontaneous regression of the primary lesion in melanoma patients illustrate a relationship between tumor immunity and autoimmunity. T lymphocytes play a major role both in tumor immunity and autoimmunity. CD28, Cytotoxic T lymphocyte antigen 4 (CTLA4) and inducible co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bouwhuis, Marna G., Gast, Andreas, Figl, Adina, Eggermont, Alexander M. M., Hemminki, Kari, Schadendorf, Dirk, Kumar, Rajiv
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2009
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2776942/ https://www.ncbi.nlm.nih.gov/pubmed/19672595 http://dx.doi.org/10.1007/s00262-009-0751-2

Ejemplares similares

Association of Inherited Variation in Toll-Like Receptor Genes with Malignant Melanoma Susceptibility and Survival
por: Gast, Andreas, et al.
Publicado: (2011)

CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
por: Pawlak-Adamska, Edyta, et al.
Publicado: (2016)

Erratum to: CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves’ disease and modulates clinical phenotype of disease
por: Pawlak-Adamska, Edyta, et al.
Publicado: (2017)

Differences in allergen-induced T cell activation between allergic asthma and rhinitis: Role of CD28, ICOS and CTLA-4
por: Botturi, Karine, et al.
Publicado: (2011)

ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade
por: Ralser, Damian J., et al.
Publicado: (2023)

B-RAF and N-RAS Mutations Are Preserved during Short Time In Vitro Propagation and Differentially Impact Prognosis
por: Ugurel, Selma, et al.
Publicado: (2007)

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
por: Fan, Xiaozhou, et al.
Publicado: (2014)

Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL fusion transcripts
por: Xie, Huaping, et al.
Publicado: (2016)

S35. Investigating the ICOS/ICOSL pathway as a target for combination therapy with anti-CTLA-4
por: Sharma, P
Publicado: (2014)

ICOS Regulates the Generation and Function of Human CD4(+) Treg in a CTLA-4 Dependent Manner
por: Zheng, Jian, et al.
Publicado: (2013)

ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity
por: Soldevilla, Mario Martínez, et al.
Publicado: (2019)

Influence of Genetic Variants in Type I Interferon Genes on Melanoma Survival and Therapy
por: Lenci, Romina Elizabeth, et al.
Publicado: (2012)

ICO investors
por: Fahlenbrach, Rüdiger, et al.
Publicado: (2020)

T cell Co-Stimulatory molecules ICOS and CD28 stratify idiopathic pulmonary fibrosis survival
por: Bonham, Catherine A., et al.
Publicado: (2019)

TGFβ2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma
por: Khanolkar, Rahul C., et al.
Publicado: (2022)

Colloque ICO '89
por: Moulin, B, et al.
Publicado: (1989)

The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy
por: Solinas, Cinzia, et al.
Publicado: (2020)

Role of endocytosis and trans‐endocytosis in ICOS costimulator‐induced downmodulation of the ICOS Ligand
por: Aragoneses‐Fenoll, Laura, et al.
Publicado: (2021)

Initial misdiagnosis of melanoma located on the foot is associated with poorer prognosis
por: Sondermann, Wiebke, et al.
Publicado: (2016)

Comprehensive analysis of the role of ICOS ( CD278 ) in pan-cancer prognosis and immunotherapy
por: Zhao, Xiashuang, et al.
Publicado: (2023)

ICOS-deficient and ICOS YF mutant mice fail to control Toxoplasma gondii infection of the brain
por: O’Brien, Carleigh A., et al.
Publicado: (2020)

Biomarkers in melanoma
por: Gogas, H., et al.
Publicado: (2009)

Informing patients about their mutation tests: CDKN2A c.256G>A in melanoma as an example
por: Hemminki, Kari, et al.
Publicado: (2020)

Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes
Publicado: (1992)

Exploring the Interactions of Oncolytic Viral Therapy and Immunotherapy of Anti-CTLA-4 for Malignant Melanoma Mice Model
por: Yu, Jui-Ling, et al.
Publicado: (2023)

Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies
por: Rujas, Edurne, et al.
Publicado: (2020)

T-Cell Mediated Immune Responses Induced in ret Transgenic Mouse Model of Malignant Melanoma
por: Abschuetz, Oliver, et al.
Publicado: (2012)

CTLA4 mRNA is downregulated by miR-155 in regulatory T cells, and reduced blood CTLA4 levels are associated with poor prognosis in metastatic melanoma patients
por: Vaddi, Prasanna Kumar, et al.
Publicado: (2023)

ARLTS1 polymorphisms and basal cell carcinoma of the skin
por: Li, Xuchen, et al.
Publicado: (2007)

Survival in melanoma in the nordic countries into the era of targeted and immunological therapies
por: Tichanek, Filip, et al.
Publicado: (2023)

CTLA4-CD28 chimera gene modification of T cells enhances the therapeutic efficacy of donor lymphocyte infusion for hematological malignancy
por: Park, Hyung Bae, et al.
Publicado: (2017)

Inhibition of Donor-Reactive CD8+ T Cell Responses by Selective CD28 Blockade Is Independent of Reduced ICOS Expression
por: Liu, Danya, et al.
Publicado: (2015)

Specific transcriptional programs differentiate ICOS from CD28 costimulatory signaling in human Naïve CD4(+) T cells
por: Gigliotti, Casimiro Luca, et al.
Publicado: (2022)

Cytotoxic T Lymphocyte Antigen 4 (CTLA4) Blockade Accelerates the Acute Rejection of Cardiac Allografts in CD28-deficient Mice: CTLA4 Can Function Independently of CD28
por: Lin, Hua, et al.
Publicado: (1998)

Regulation of T follicular helper cells by ICOS
por: Hutloff, Andreas
Publicado: (2015)

ICOS regulates ILC2s in asthma
por: Maazi, Hadi, et al.
Publicado: (2015)

ICOS Co-Stimulation: Friend or Foe?
por: Wikenheiser, Daniel J., et al.
Publicado: (2016)

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
Publicado: (1995)

Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report
por: Matull, Johanna, et al.
Publicado: (2020)

Risk of other Cancers in Families with Melanoma: Novel Familial Links
por: Frank, Christoph, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_c6kuh5it072c4ohqoao63tcb15